Impact of a selective cyclooxygenase-2 inhibitor, celecoxib, on cortical excitability and electrophysiological properties of the brain in healthy volunteers: A randomized, double-blind, placebo-controlled study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Electroencephalography*; Anticonvulsants/*administration & dosage ; Celecoxib/*administration & dosage ; Cerebral Cortex/*physiopathology ; Cortical Excitability/*drug effects ; Cyclooxygenase 2 Inhibitors/*administration & dosage; Adult ; Double-Blind Method ; Female ; Humans ; Male
    • Abstract:
      The inflammatory response is considered a defence mechanism against physical or infectious insults and is prevalent within the central nervous system. Seizures also result in a robust inflammatory cascade, leading to enhanced activation of excitatory synaptic networks. Ample evidence based on animal models of epilepsy has demonstrated that celecoxib, a highly selective inhibitor of cyclooxygenase-2, has anticonvulsant effects. We aimed to evaluate the impact of celecoxib on the cortical excitability and electrophysiological properties of the brain in healthy humans. Electroencephalography (EEG) or transmagnetic stimulation (TMS) was used to measure neurophysiological activity. Forty healthy volunteers were randomized to 4 groups (n = 10 in each group): 1) celecoxib and EEG, 2) placebo and EEG, 3) celecoxib and TMS, and 4) placebo and TMS. For the EEG study, resting EEG was performed at baseline just before administering 400 mg of celecoxib or placebo and repeated 4 hours after administration. The subjects took 200 mg of celecoxib or placebo twice a day for 7 subsequent days, and a third EEG was conducted 4 hours after the final dose. Power spectra were compared at each time point. For the TMS study, the resting motor threshold (RMT), motor evoked potential (MEP) peak-to-peak amplitude, and cortical silent period (CSP) were measured at baseline and after taking 200 mg of celecoxib or placebo twice a day for 7 days. Celecoxib did not significantly change brain activity in the EEG study. However, the sum of power recorded from all electrodes tended to increase in the celecoxib group only at 4 hours after administration (p = 0.06). In detail, one dose of celecoxib (400 mg) transiently and significantly increased the alpha band power recorded in the frontal and parietal areas as well as in the whole brain (p = 0.049, 0.017, and 0.014, respectively) and the beta frequency in the central and parietal regions (p = 0.013 and 0.005, respectively), whereas the placebo did not. This effect was abolished after 7 days of treatment. In the TMS study, we found no statistically significant change in the RMT, MEP peak-to-peak amplitude or CSP. This evidence suggests that celecoxib transiently alters the electrophysiological properties of the brain but does not suppress neuronal excitability in healthy humans.
      Competing Interests: This study was funded by Pfizer Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      Nat Rev Neurol. 2011 Jan;7(1):31-40. (PMID: 21135885)
      Epilepsia. 2003 Aug;44(8):1042-50. (PMID: 12887435)
      J Neurosci. 1998 Aug 15;18(16):6599-607. (PMID: 9698346)
      J Neurosci. 2006 Oct 25;26(43):11083-110. (PMID: 17065450)
      Sleep Med. 2011 Apr;12(4):416-21. (PMID: 21377421)
      Exp Brain Res. 1998 Sep;122(1):79-84. (PMID: 9772114)
      Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):205-16. (PMID: 14518562)
      Exp Brain Res. 2000 Dec;135(4):504-10. (PMID: 11156314)
      Neurobiol Dis. 2004 Dec;17(3):385-402. (PMID: 15571975)
      Clin Neurophysiol. 2008 Jun;119(6):1385-92. (PMID: 18396455)
      Br J Pharmacol. 2010 Jul;160(5):1062-71. (PMID: 20590600)
      Neurobiol Dis. 2006 Aug;23(2):237-46. (PMID: 16806953)
      Epilepsia. 2002 May;43(5):482-90. (PMID: 12027908)
      Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11053-8. (PMID: 12958209)
      Neurobiol Dis. 2004 Jul;16(2):321-34. (PMID: 15193289)
      N Engl J Med. 2006 Aug 31;355(9):873-84. (PMID: 16943400)
      Nat Rev Neurosci. 2002 Mar;3(3):216-27. (PMID: 11994753)
      Exp Brain Res. 1999 Feb;124(4):447-54. (PMID: 10090656)
      Exp Brain Res. 1999 Mar;125(1):82-6. (PMID: 10100980)
      Ann Clin Transl Neurol. 2016 Oct 18;3(12):908-923. (PMID: 28097203)
      Brain Behav Immun. 2003 Feb;17 Suppl 1:S41-7. (PMID: 12615185)
      Neuroscience. 2004;125(2):317-27. (PMID: 15062975)
      Ann N Y Acad Sci. 2001 Mar;933:211-21. (PMID: 12000022)
      Neuroscience. 2017 Jan 6;340:258-267. (PMID: 27815021)
      Epilepsy Res. 2010 Sep;91(1):57-65. (PMID: 20655707)
      Brain Res. 1999 Oct 2;843(1-2):118-29. (PMID: 10528118)
    • Accession Number:
      0 (Anticonvulsants)
      0 (Cyclooxygenase 2 Inhibitors)
      JCX84Q7J1L (Celecoxib)
    • Publication Date:
      Date Created: 20190223 Date Completed: 20191121 Latest Revision: 20200309
    • Publication Date:
      20221213
    • Accession Number:
      PMC6386435
    • Accession Number:
      10.1371/journal.pone.0212689
    • Accession Number:
      30794658